omeprazole and citalopram

omeprazole has been researched along with citalopram in 25 studies

Research

Studies (25)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's13 (52.00)29.6817
2010's12 (48.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Topliss, JG; Yoshida, F1
Gao, F; Lombardo, F; Obach, RS; Shalaeva, MY1
Li, Y; Li, YH; Wang, YH; Yang, L; Yang, SL1
Lombardo, F; Obach, RS; Waters, NJ1
Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV1
Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A1
Choi, SS; Contrera, JF; Hastings, KL; Kruhlak, NL; Sancilio, LF; Weaver, JL; Willard, JM1
Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV1
García-Mera, X; González-Díaz, H; Prado-Prado, FJ1
Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ1
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K1
Malling, D; Poulsen, MN; Søgaard, B1
Haataja, R; Huuhka, K; Leinonen, E; Riutta, A; Ylitalo, P1
de Leon, J1
Jerome, L1
Andersson, M; Baldwin, RM; Bertilsson, L; Eliasson, E; Ingelman-Sundberg, M; Mwinyi, J; Ohlsson Rosenborg, S; Pedersen, RS; Sim, SC1
Ferringer, T; Lountzis, NI; Puri, PK; Tyler, W1
Barasain, MA; Sasich, LD; Sukkari, SR1
Coelho, EB; Lanchote, VL; Rocha, A; Sampaio, SA1
Bourke, J; Roper, S1
Bagheri, H; Caillet, C; Chauvelot-Moachon, L; Montastruc, JL1
Bibian, C; Constante, Y; Garcia-Arilla, E; Gil, J; Lozano, R; Quilez, RM1
Dolkart, O; Gigi, R; Katzburg, S; Salai, M; Somjen, D; Yakobson, O1
Charitos, C; Kapelios, CJ; Tsamatsoulis, M1
Chen, YC; Chou, YC; Hung, CF; Ku, PM; Sun, CA; Tsai, CT; Wu, WT; You, SL1

Reviews

2 review(s) available for omeprazole and citalopram

ArticleYear
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
    Drug discovery today, 2016, Volume: 21, Issue:4

    Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk

2016
The crucial role of the therapeutic window in understanding the clinical relevance of the poor versus the ultrarapid metabolizer phenotypes in subjects taking drugs metabolized by CYP2D6 or CYP2C19.
    Journal of clinical psychopharmacology, 2007, Volume: 27, Issue:3

    Topics: Alleles; Anti-Ulcer Agents; Antidepressive Agents, Tricyclic; Aryl Hydrocarbon Hydroxylases; Atomoxetine Hydrochloride; Citalopram; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP2D6; Genetic Variation; Humans; Mixed Function Oxygenases; Omeprazole; Pharmacogenetics; Phenotype; Propylamines; Racial Groups

2007

Trials

4 trial(s) available for omeprazole and citalopram

ArticleYear
The effect of cimetidine or omeprazole on the pharmacokinetics of escitalopram in healthy subjects.
    British journal of clinical pharmacology, 2005, Volume: 60, Issue:3

    Topics: Adolescent; Adult; Anti-Ulcer Agents; Cimetidine; Citalopram; Depressive Disorder; Drug Therapy, Combination; Female; Histamine H2 Antagonists; Humans; Male; Middle Aged; Omeprazole; Selective Serotonin Reuptake Inhibitors

2005
The effect of CYP2C19 substrate on the metabolism of melatonin in the elderly: A randomized, double-blind, placebo-controlled study.
    Methods and findings in experimental and clinical pharmacology, 2006, Volume: 28, Issue:7

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Aged, 80 and over; Anticonvulsants; Antidepressive Agents, Second-Generation; Aryl Hydrocarbon Hydroxylases; Citalopram; Cytochrome P-450 CYP2C19; Double-Blind Method; Drug Therapy, Combination; Enzyme Inhibitors; Female; Humans; Lansoprazole; Male; Melatonin; Mental Disorders; Mixed Function Oxygenases; Omeprazole; Selective Serotonin Reuptake Inhibitors; Sleep Wake Disorders; Time Factors; Treatment Outcome

2006
Kinetics of omeprazole and escitalopram in relation to the CYP2C19*17 allele in healthy subjects.
    European journal of clinical pharmacology, 2008, Volume: 64, Issue:12

    Topics: Adult; Alleles; Anti-Ulcer Agents; Antidepressive Agents, Second-Generation; Area Under Curve; Aryl Hydrocarbon Hydroxylases; Citalopram; Cytochrome P-450 CYP2C19; Drug Administration Schedule; Female; Genotype; Humans; Male; Metabolic Clearance Rate; Middle Aged; Omeprazole; Substrate Specificity; Young Adult

2008
Omeprazole preferentially inhibits the metabolism of (+)-(S)-citalopram in healthy volunteers.
    British journal of clinical pharmacology, 2010, Volume: 70, Issue:1

    Topics: Adult; Aryl Hydrocarbon Hydroxylases; Citalopram; Cross-Over Studies; Cytochrome P-450 CYP2C19; Drug Interactions; Female; Humans; Male; Omeprazole; Selective Serotonin Reuptake Inhibitors; Young Adult

2010

Other Studies

19 other study(ies) available for omeprazole and citalopram

ArticleYear
QSAR model for drug human oral bioavailability.
    Journal of medicinal chemistry, 2000, Jun-29, Volume: 43, Issue:13

    Topics: Administration, Oral; Biological Availability; Humans; Models, Biological; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship

2000
Prediction of human volume of distribution values for neutral and basic drugs. 2. Extended data set and leave-class-out statistics.
    Journal of medicinal chemistry, 2004, Feb-26, Volume: 47, Issue:5

    Topics: Algorithms; Blood Proteins; Half-Life; Humans; Hydrogen-Ion Concentration; Models, Biological; Pharmaceutical Preparations; Pharmacokinetics; Protein Binding; Statistics as Topic; Tissue Distribution

2004
Modeling K(m) values using electrotopological state: substrates for cytochrome P450 3A4-mediated metabolism.
    Bioorganic & medicinal chemistry letters, 2005, Sep-15, Volume: 15, Issue:18

    Topics: Computational Biology; Cyclohexanols; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Molecular Structure; Principal Component Analysis; Pyrrolizidine Alkaloids; Quantitative Structure-Activity Relationship; Reproducibility of Results; Substrate Specificity; Venlafaxine Hydrochloride

2005
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
    Drug metabolism and disposition: the biological fate of chemicals, 2008, Volume: 36, Issue:7

    Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding

2008
Physicochemical determinants of human renal clearance.
    Journal of medicinal chemistry, 2009, Aug-13, Volume: 52, Issue:15

    Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight

2009
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
    Chemical research in toxicology, 2010, Volume: 23, Issue:1

    Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship

2010
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
    Toxicology mechanisms and methods, 2008, Volume: 18, Issue:2-3

    Topics:

2008
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
    Journal of medicinal chemistry, 2010, Feb-11, Volume: 53, Issue:3

    Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations

2010
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
    Bioorganic & medicinal chemistry, 2010, Mar-15, Volume: 18, Issue:6

    Topics: Antiparasitic Agents; Molecular Structure; Neural Networks, Computer; Parasitic Diseases; Quantitative Structure-Activity Relationship; Species Specificity; Thermodynamics

2010
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
    Toxicological sciences : an official journal of the Society of Toxicology, 2013, Volume: 136, Issue:1

    Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests

2013
Pregabalin-induced remission in a 62-year-old woman with a 20-year history of vulvodynia.
    Pain research & management, 2007,Autumn, Volume: 12, Issue:3

    Topics: Amitriptyline; Analgesics; Anti-Ulcer Agents; Anticoagulants; Antidepressive Agents; Anxiety; Cardiotonic Agents; Cataract; Cataract Extraction; Cholecystectomy; Chronic Disease; Citalopram; Digoxin; Female; gamma-Aminobutyric Acid; Heart Failure; Humans; Hypertension; Hysterectomy; Lorazepam; Middle Aged; Mitral Valve Insufficiency; Omeprazole; Ovarian Neoplasms; Pain; Pregabalin; Sterilization, Tubal; Stomach Diseases; Vulvar Diseases

2007
Hydroxychloroquine-induced hyperpigmentation: the staining pattern.
    Journal of cutaneous pathology, 2008, Volume: 35, Issue:12

    Topics: Aged; Antacids; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Antirheumatic Agents; Arthritis, Rheumatoid; Aspirin; Atorvastatin; Calcium Carbonate; Cardiomyopathy, Restrictive; Citalopram; Connective Tissue Diseases; Diuretics; Female; Furosemide; Glucosamine; Heptanoic Acids; Humans; Hydroxychloroquine; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperpigmentation; Lupus Erythematosus, Systemic; Magnesium; Metolazone; Middle Aged; Naproxen; Omeprazole; Potassium Chloride; Prednisone; Pyrroles; Selective Serotonin Reuptake Inhibitors; Spironolactone

2008
An academic perspective on the APPEs' educational significance.
    American journal of pharmaceutical education, 2009, Dec-17, Volume: 73, Issue:8

    Topics: Accreditation; Acetates; Citalopram; Cyclopropanes; Drug Labeling; Education, Pharmacy; Evidence-Based Medicine; Humans; Leukotriene Antagonists; Omeprazole; Practice Guidelines as Topic; Problem-Based Learning; Proton Pump Inhibitors; Quinolines; Schools, Pharmacy; Selective Serotonin Reuptake Inhibitors; Sulfides; United States

2009
In with the new: the determinants of prescribing innovation by general practitioners in Ireland.
    The European journal of health economics : HEPAC : health economics in prevention and care, 2012, Volume: 13, Issue:4

    Topics: Age Factors; Androstenes; Citalopram; Drug Prescriptions; Drug Utilization; Ethinyl Estradiol; General Practitioners; Humans; Information Dissemination; Insurance Claim Review; Ireland; Lactones; Loratadine; Nicotine; Omeprazole; Practice Patterns, Physicians'; Residence Characteristics; Sulfones; Therapies, Investigational; Time Factors

2012
Safety profile of enantiomers vs. racemic mixtures: it's the same?
    British journal of clinical pharmacology, 2012, Volume: 74, Issue:5

    Topics: Adult; Adverse Drug Reaction Reporting Systems; Aged; Aged, 80 and over; Cetirizine; Citalopram; Databases, Factual; Female; Humans; Levofloxacin; Male; Middle Aged; Ofloxacin; Omeprazole; Stereoisomerism; Young Adult

2012
Clinical relevance of the (S)-citalopram-omeprazole interaction in geriatric patients.
    British journal of clinical pharmacology, 2014, Volume: 77, Issue:6

    Topics: Aged; Citalopram; Cytochrome P-450 CYP2C19 Inhibitors; Electrocardiography; Female; Humans; Male; Omeprazole; Prospective Studies; Selective Serotonin Reuptake Inhibitors

2014
Effects of commonly used medications on bone tissue mineralisation in SaOS-2 human bone cell line: an in vitro study.
    The bone & joint journal, 2013, Volume: 95-B, Issue:11

    Topics: Adrenergic beta-1 Receptor Antagonists; Bone and Bones; Calcification, Physiologic; Cell Line; Cell Proliferation; Citalopram; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemic Agents; Metformin; Metoprolol; Omeprazole; Osteoblasts; Proton Pump Inhibitors; Pyrimidines; Rosuvastatin Calcium; Selective Serotonin Reuptake Inhibitors; Sulfonamides

2013
Hyperpyrexia in a patient with a left ventricular assist device: a diagnosis beyond the obvious.
    Interactive cardiovascular and thoracic surgery, 2018, 05-01, Volume: 26, Issue:5

    Topics: Aged; Citalopram; Fever; Heart Failure; Heart-Assist Devices; Humans; Male; Omeprazole; Proton Pump Inhibitors; Selective Serotonin Reuptake Inhibitors; Serotonin Syndrome

2018
Cardiovascular Outcomes Associated With Clinical Use of Citalopram and Omeprazole: A Nationwide Population-Based Cohort Study.
    Journal of the American Heart Association, 2019, 10-15, Volume: 8, Issue:20

    Topics: Cardiovascular Diseases; Citalopram; Death, Sudden, Cardiac; Drug Therapy, Combination; Female; Follow-Up Studies; Forecasting; Humans; Incidence; Male; Middle Aged; Omeprazole; Population Surveillance; Proton Pump Inhibitors; Retrospective Studies; Risk Assessment; Risk Factors; Selective Serotonin Reuptake Inhibitors; Survival Rate; Taiwan

2019